Pioglitazone News and Research

RSS
Long-term linagliptin effective treatment for Type 2 diabetes

Long-term linagliptin effective treatment for Type 2 diabetes

Linagliptin safe and effective for long-term management of type 2 diabetes

Linagliptin safe and effective for long-term management of type 2 diabetes

Diabetes drug raises bladder cancer risk

Diabetes drug raises bladder cancer risk

Pioglitazone may raise bladder cancer risk

Pioglitazone may raise bladder cancer risk

Pioglitazone may raise bladder cancer risk

Pioglitazone may raise bladder cancer risk

Standard aspirin dose may not protect diabetics against blood clots

Standard aspirin dose may not protect diabetics against blood clots

Clinical utility of Metabolon's Quantose IR test to be showcased at ADA meeting

Clinical utility of Metabolon's Quantose IR test to be showcased at ADA meeting

Thiazolidinedione drugs linked with increased risk of DME in patients with Type 2 diabetes

Thiazolidinedione drugs linked with increased risk of DME in patients with Type 2 diabetes

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Researchers identify new mitochondrial protein complex linked with type 2 diabetes

Researchers identify new mitochondrial protein complex linked with type 2 diabetes

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

Investigational diabetes drug appears to improve insulin sensitivity without side effects

Investigational diabetes drug appears to improve insulin sensitivity without side effects

Increased risk of bladder cancer linked to diabetes drug

Increased risk of bladder cancer linked to diabetes drug

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

European Commission grants marketing authorization for use of BYETTA with basal insulin

European Commission grants marketing authorization for use of BYETTA with basal insulin

Weight gain or loss may also depend on medicines taken

Weight gain or loss may also depend on medicines taken

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Pioglitazone can prevent long term effects of maternal obesity on offspring

Pioglitazone can prevent long term effects of maternal obesity on offspring

Length of residence in the U.S. increases risk of PTB among Hispanic women

Length of residence in the U.S. increases risk of PTB among Hispanic women

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes